Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247 Press Release 09.18.2024 Read the press release at ir.satellos.com: Drug Target Review: Advancing Muscle Repair In The News Press Release 09.18.2024 Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247 In the News 08.08.2024 Clinical Trials Arena: Satellos to Commence Phase 1 Trial for DMD Drug Press Release 08.08.2024 Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy In the News 07.02.2024 Pharmaphorum Podcast: The Power and Potential of Regenerative Medicine Press Release 07.11.2024 Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247 In the News 06.24.2024 Drug Target Review Podcast: Small Molecules for Regenerative Medicine In the News 05.30.2024 Satellos Receives Company of the Year Award from Life Sciences Ontario Press Release 05.28.2024 Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy In the News 05.23.2024 Radius Research Webinar | Satellos Product Development and Milestones In the News 04.18.2024 RareCast: A Small Molecule Therapy to Regenerate Muscle in People with DMD In the News 04.17.2024 Destroy Duchenne Podcast: Pioneering Duchenne Muscular Dystrophy Treatment with Satellos | Elijah Stacy & Dr. Rudnicki In the News 03.21.2024 Developing a Small Molecule for Duchenne Muscular Dystrophy with Frank Gleeson | VibeCast Episode 48 Press Release 03.04.2024 Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference In the News 02.20.2024 MD News Today: SAT-3247 Improves Muscle Function in FSHD Mouse Model Press Release 02.20.2024 Satellos Announces Upcoming Presentations at the 2024 MDA Clinical & Scientific Conference Press Release 02.21.2024 Satellos Recognized as a Top 50 TSX Venture Exchange Company Press Release 02.14.2024 Satellos to Commence Trading on the Toronto Stock Exchange Press Release 02.13.2024 Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy In the News 01.24.2024 Satellos CEO Frank Gleeson Speaks with pharmaphorum at JPM24 Press Release 01.16.2024 Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange In the News 01.15.2024 Life Sciences Ontario Announces Recipients of 2024 LSO Awards Press Release 11.14.2023 SATELLOS Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program In the News 10.10.2023 Drug Target Review: Advancing Muscle Repair Back Discover About Duchenne Science MyoReGenX™ Investors Careers News
